Skip to content

Author

ML Rakoto

We have 1 of 1 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

PSGL-1 blockade delays relapse to BRAF/MEK inhibition in cutaneous melanoma

It is demonstrated that dual inhibition of BRAF/MEK and PSGL-1 elicits durable tumor control in a preclinical model of PD-1-refractory cutaneous melanoma, and antibody-mediated blockade of PSGL-1, in combination with BRAF/MEK inhibition, yields superior anti-tumor activity compared with either monotherapy.

O. E. El Naggar, Bn. Ha, ML Rakoto et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.